France-based Diabeloop, whose AI-based diabetes management tech automatically adjusts insulin delivery as needed, raises a €70M Series C led by LBO France
Andrea Park / Fierce Biotech :
Context & Ripple Effects
Diabeloop's €70M Series C lands in a category where capital has been following clinical validation: Beta Bionics' $100M Series D came on the back of an FDA approval for its automated insulin dosing software, showing that regulators clearing closed-loop systems unlocks nine-figure rounds. Diabeloop is the European counterpart — same thesis of AI adjusting insulin delivery automatically, but raising under LBO France rather than U.S. growth investors.
The round also extends a broader European digital-health funding line: Oviva's Series B backed a tech-based approach to Type 2 diabetes treatment in Europe two years earlier, so France-based Diabeloop is scaling in a region where payers and investors have already warmed to software-first diabetes care.
First-order effects
- Diabeloop gains €70M of new runway from LBO France to push its automatic insulin-adjustment technology through development and commercialization, while Beta Bionics' FDA-cleared dosing software sets the competitive bar it must clear.
Second-order effects
- Insulin pump makers and glucose-monitoring suppliers become the swing partners: whichever algorithm platform they integrate with gains distribution, forcing device vendors to pick sides between Diabeloop and rivals like Beta Bionics.
Third-order effects
- If the pattern holds — approval first, mega-round second — diabetes management consolidates around a handful of well-funded closed-loop algorithm platforms, with regional champions (Beta Bionics in the U.S., Diabeloop in Europe) racing toward each other's markets.
The trend: Venture capital is treating AI-driven automated insulin delivery as a distinct, approval-gated category where regulatory wins trigger outsized rounds.